Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Woodford to meet Pfizer chief about AstraZeneca deal

Woodford to meet Pfizer chief about AstraZeneca deal

Neil Woodford is to meet the chief executive of Pfizer to discuss its bid for AstraZeneca.

According to Sky News, the star fund manager will sit down with Ian Read, the US giant’s boss, to talk through his concerns about the deal.

Woodford (pictured) has been a long-term backer of AstraZeneca and earlier this month said that he believes the company ‘has an exciting future as an independent entity’.

AstraZeneca rejected an improved offer of £63 billion, saying the amount ‘significantly undervalued AstraZeneca and its prospects’.

The stock is expected to be a key component of the newly launched Woodford Investment Management’s Income fund, which comes to market next month.

It is set to be another busy week for Read who today goes before MPs on the Business, Innovation and Skills Select Committee to discuss his plans for the combined business, should a deal go through. A number of politicians have raised concerns about the potential loss of jobs following a merger.

Yesterday Axa Framlington's AA-rated Nigel Thomas said that he been buying AstraZeneca shares ahead of the bid aproach, feeling its advances in cancer treatments was undervalued by the market.

He said: 'While approaching the subject as a layman, the basic tenet of the research is that cancer can be transformed from a terminal illness to a chronic disease through immunotherapy.

‘We have purchased shares in AstraZeneca in the last six months; their predicament of significant revenue-earning patent expiries over the next few years has been heavily discounted by the stock market.

‘However, behind the other three companies, Astra’s portfolio of compounds is notable due to their expertise, with existing drugs across a wide spread of clinical outcomes. Given that many immunotherapies will incorporate other drugs in "combination therapies", AstraZeneca will have the option to commercialise a great deal of in-house compounds to late stage trials.'

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Kames' Ennett: Trump good for US high yield, but beware Europe

Kames' Ennett: Trump good for US high yield, but beware Europe

Kames Capital’s head of high yield David Ennett believes the changing political landscape will be a positive for the US, but negative for Europe in 2017.

Play Philip Milburn: why inflation won't run out of control

Philip Milburn: why inflation won't run out of control

Kames bond fund manager views inflation as more of 'scare' than a 'problem' and is positioning his portfolios accordingly.

Play Henderson's Lofthouse on merger boost and political risk

Henderson's Lofthouse on merger boost and political risk

Ben Lofthouse talks through where he is finding income and what surprises await the global economy in the new year.

Read More
Your Business: Cover Star Club

Profile: why Patronus Partners' founder left the only job he ever knew

Profile: why Patronus Partners' founder left the only job he ever knew

'There was a definite idea of how things would work out over 12 months. When we look back, that was inaccurate'

Wealth Manager on Twitter